Page 6 - lifepak

8
Placebo
7
LifePak
6
5
4
3.5
3.4
3
2
1
0
Baseline Endpoint
38%
140
p < 0.001
89%
120
LifePak
(means +/- SD)
Placebo
7
100
LifePak
p < 0.001
94.3
6
80
60 8 Placebo 3.3 89% p < 0.001 6.2 6.2
70.6
5
67.4
68.1
40
COMPETITIVE ADVANTAGES 4 3.4 3.5
20
3
KELEBIHAN PERSAINGAN 0 2 3.3
Baseline Endpoint
1
1. LifePak® is the first clinically proven comprehensive nutritional supplement
0
LifePak® adalah suplemen bernutrisi komprehensif yang pertama dibuktikan secara klinikal
Baseline Endpoint
1200
Unlike other multivitamin/mineral products, LifePak® is supported by two double-blind, 210%
placebo-controlled clinical studies, a 150-subject parallel design study and a 50-subject
1
crossover study . 89% 1000 Placebo
2
LifePak
8
Conclusion: Both studies tested the antioxidant effects of LifePak® in healthy 38%
p < 0.001
140
Placebo
non-smokers and found a marked improvement in their antioxidants status. Placebo p < 0.001
7
800
120
LifePak
p < 0.001
LifePak
Tidak seperti produk multivitamin/mineral yang lain, LifePak® turut disokong oleh dua (means +/- SD)
6
100
6.2
jenis ujian klinikal dwi-buta, kawalan-plasebo, yang melibatkan kajian rekabentuk selari 716
1
terhadap 150 subjek dan kajian langkauan kepada 50 subjek. 600 80 94.3
5
2
60
Kesimpulan: Kedua-dua kajian menguji kesan antioksidan LifePak® di kalangan bukan-perokok 68.1 70.6
4
67.4
yang sihat dan mendapati peningkatan status antioksidan yang tinggi. 400 40
3.5
3
1 Source Sumber: 3.4 3.3 331 335
20
Smidt, C.R., Woehler, D.L., Seidehamel, R.J., Devaraj, S., Jialal, I. (2008). Double-Blind, Placebo-Controlled Study of the Effects of LifePak® 299
2
200
Supplementation on Antioxidant Status, Free Radical Activity and Resistance to LDL-Oxidation. Journal of the American Nutraceutical
0
Association, Vol.1, No.2.
1
2 Source Sumber: Baseline Endpoint
Graph 2: Serum -carotene
0
Smidt, C.R., Seidehamel, R.J., Devaraj, S., Jialal, I. (1999). The Effects of a Nutritionally Complete Dietary Supplement (LifePak®) on Antioxidant
Graf 2: Serum-karotena
0
Status and LDL-Oxidation in Healthy Non-Smokers. FASEB, 13(4), A546 Baseline Endpoint
Baseline Endpoint
Graph 1: Serum Vitamin C
210%
Graf 1: Serum Vitamin C 1200 114%
Placebo
38% 1000 LifePak ®
1000
38%
140 p < 0.001 770% p < 0.001
120 Placebo 800 Placebo
LifePak ® (means +/- SD) 800 LifePak
100 600 p < 0.001 716
80 94.3 592
60 67.4 68.1 70.6 600
400
40 331 335 299
200
20 400
0 0 76.6 84.9
Baseline Endpoint 200 Baseline Endpoint
121
Graph 4: LDL Protection
0
Graph 3: Serum Vitamin E (LDL oxidizability, lag time (min))
Baseline Endpoint
1200
Graf 3: Serum Vitamin E 210% Graf 4: Perlindungan LDL
1000
770%
Placebo (Keupayaan oksidasi LDL, masa lag (min))
1000 LifePak p < 0.001 Placebo
LifePak
800
89%
17%
8
800 88% 65 17% p < 0.001
592
7 Placebo ® 716 60 Placebo ® p < 0.001
600
600 LifePak p < 0.001 6.2 LifePak
6
5 55
400
400 50
4 76.6 50.9
331 335 299 84.9
200
200 3.4 3.3 3.5 45
3
2 40 42.1 121 43.4 42
0 0
1 Baseline Endpoint 35 Baseline Endpoint
0 30
Baseline Endpoint Baseline Endpoint
Note Kenyataan: 65 17%
1000
770%
Graph 1-4 above are the clinical results from study . 2 Placebo p < 0.001
38%
Graf 1-4 di atas merupakan hasil-hasil ujian dari kajian . 2 60 LifePak
Placebo
140
800 LifePak p < 0.001 55
Placebo
120 p < 0.001
LifePak (means +/- SD)
100 592 50 50.9
600 94.3
80 45
60 67.4 68.1 70.6 40 42.1 43.4 42
400
40 35
20 76.6 84.9
200 30
0 Baseline Endpoint
Baseline Endpoint
121
0
Baseline Endpoint
1200 210%
Placebo
1000 LifePak
65 17%
p < 0.001
Placebo p < 0.001
60
800 LifePak
55 716
600
50 50.9
400
45
331 335 299
40
200 42.1 43.4 42
35
0
30 Baseline Endpoint
Baseline Endpoint
1000 770%
Placebo
800 LifePak
p < 0.001
592
600
400
76.6 84.9
200
121
0
Baseline Endpoint
65 17%
Placebo p < 0.001
60 LifePak
55
50 50.9
45
40 42.1 43.4 42
35
30
Baseline Endpoint